Rescue of the Mucocutaneous Manifestations in a Mouse Model of Recessive Dystrophic Epidermolysis Bullosa (RDEB) By Human Cord Blood Derived Unrestricted Somatic Stem Cells (USSCs)  by Rashad, Ahmed et al.
Biol Blood Marrow Transplant 21 (2015) S240eS265SOLID TUMORS326
Improved Outcomes Following Drug-Resistant
Immunotherapy in a Hunan Xenograft Model of
Temozolomide-Resistant Glioblastoma Multiforme
Harold Trent Spencer 1, Anindya Dasgupta 1,
George Yancey Gillespie 2, Larisa Pereboeva 3,
Kathryn S. Sutton 1, Lawrence Lamb 3. 1 Pediatrics, Emory
University School of Medicine, Atlanta, GA; 2Neurosurgery,
University of Alabama at Birmingham, Birmingham, AL;
3Medicine, University of Alabama at Birmingham,
Birmingham, AL
Introduction: Conventional treatment strategies for Temo-
zolomide (TMZ)-resistant high-grade gliomas have been
uniformly dismal. Our previous studies have shown that
TMZ-resistant tumors upregulate stress-associated NKG2D
ligands (NKG2DL) during the ﬁrst several hours following
exposure to TMZ, thereby creating an opportunity for
NKG2DL-directed cell therapy, particularly ex vivo expanded/
activated gd T cells and NK cells that directly recognize
these stress-associated antigens. Using a human/mouse
primary xenograft model, we report improved survival
using a combination of TMZ chemotherapy and gene
modiﬁed TMZ-resistant gd T cells + NK cells which we
term Drug Resistant Immunotherapy (DRI). Drug resistance
is conferred by lentivector transfer of methylguanine
methyltransferase (MGMT), enabling cytotoxic lymphocyte
function in a chemotherapy-rich environment at a time
when the tumor is maximally stressed and regulatory T cells
are depleted.
Methods: Tumor NKG2DL expression and cytotoxicity of DRI
were assessed using ﬂow cytometry. Intracranial (IC) glioma
xenografts were established in immunodeﬁcient mice using
either an unmodiﬁed (P) or a TMZ-resistant clone (T) of
human GBM-X12 primary explants. Tumor-bearing mice
were treated with an intraperitoneal 60mg/kg dose of TMZ
on days 6, 8,13, and 15 post-tumor placement and received IC
injection of 1.5 x 106DRI 1x/week x 2weeks on post-injection
days 7 and 14 or 2x/week x 2 weeks following each TMZ dose
by 4h. Control mice received non-modiﬁed cells, TMZ alone
or no therapy. Survival was assessed using Kaplan-Meier
analysis.
Results: Both GBM-X12P and X12T express stress antigens
MIC-A, MIC-B, and ULBP-4. DRI cells tested for potency in
vitro killed both tumors at approximately 80% at an effector:
target ratio of 20:1 and showed no evidence of toxicity
against cultured human astrocytes. Cell therapy alone did not
improve survival beyond that of untreated mice for either
tumor. For the unmodiﬁed parent tumor X12P, both TMZ
therapy and TMZ + DRI signiﬁcantly improved survival over
untreated controls (p < 0.0001), and the combined therapy
increased median survival from 57 to 75 days over TMZ
alone. Combined therapy with TMZ + DRI also marginally
improved survival for X12T (p ¼ 0.0147) extending median
survival over TMZ alone from 22 to 27 days (p ¼ 0.0966).
Keeping the TMZ dosing schedule constant, intensiﬁcation
of DRI therapy from 1x/week to 2x/week increased
median survival from 22 days to 38 days over untreated
animals (p ¼ 0.0004) and signiﬁcantly improved median
survival over TMZ-treated animals from 27 to 38 days
(p ¼ 0.0017) with 10% of animals showing long-term
survival.Conclusions: The combination of chemotherapy-induced
tumor stress and targeted DRI signiﬁcantly increases time to
progression and improves survival in immunodeﬁcient
mice bearing otherwise impervious temozolomide-resistant
human xenograft tumors.327
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Neuroblastoma is the most common solid tumor in pediatric
patients, with a clear unmet need as survival rates are <20%
for stage IV disease. As adjuvant immunotherapy is
considered to have additional anti-tumor activity we aim to
increase cytotoxic T lymphocyte (CTL)-mediated immune
surveillance in neuroblastoma patients by administration of
a dendritic cell-based vaccine. Neuroblastoma has developed
mechanisms to circumvent CTL recognition; therefore it is
our aim to ﬁnd clinical strategies to make neuroblastoma
susceptible for CTL killing. PRAME is highly expressed in
stage IV primary neuroblastoma and PRAME-derived
antigenic peptide can be presented as peptide/MHC I
complexes to reactive T cells. LowMHC I expression levels on
neuroblastoma cells enable them to escape CTL recognition,
but MHC I levels can be increased by interferon-gamma
(IFNg). Because of the clinical toxic effects of IFNg adminis-
tration, we attempted to deliver IFNg to neuroblastoma via
alternative routes. We added natural killer (NK) cells which
recognize target cells by their lack of MHC I and found that
NK cell recognition of neuroblastoma cells upregulated class
I MHC surface expression. This effect was contact-dependent,
however could thereafter be transferred to “naïve” neuro-
blastoma cells through replacement of culture supernatant.
Interestingly, IFNg was not detected in the supernatants,
suggesting a different factor that triggers the MHC I
upregulation in neuroblastoma. Importantly, PRAME-speciﬁc
T cells were speciﬁcally activated by neuroblastoma cells
after exposure to NK cells. In conclusion; we showed that NK
cells can regulate MHC I levels on neuroblastoma cells which
transforms them into CTL targets.STEM CELL BIOLOGY328
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Figure 1. (A). Skin phenotypes of a RDEB mouse after birth (DO), on D7 and D16 demonstrating amelioration of hemorrhagic blisters following a single USSC
intrahepatic treatment. (B). Kaplan-Meier survival curves of the RDEB mice that received PBS, a single intrahepatic USSC and repeated intrahepatic USSC injections.
(C). H&E staining of the paws of RDEB mice on different days following a single USSC intrahepatic injection.
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Background: RDEB is a severe inherited skin blistering dis-
ease caused by mutations in the COL7A1 gene that encodes
type VII collagen (C7), a major component in the anchoring
ﬁbrils at the basement membrane. Allogeneic stem cell
transplantation in both experimental animals and human
subjects with RDEB resulted in increased C7 deposition and
alleviation of the blistering phenotype in some recipients
(Kiuru/Cairo/Christiano et al 2011). However, there was no
distinct anchoring ﬁbril formation in the recipient skin and
the effective cell types that contribute to the regeneration in
RDEB skin remain to be identiﬁed. Our previous studies
demonstrated that CB-derived USSCs express C7 and
promote epithelialization and wound closure in a murine
wound healing model (Liao/Cairo et al Cell Transplant 2014).
Methods: CB-derived USSCs were labeled with GFP/Luc
reporter gene and injected in newborn col7a1-/- (RDEB) mice
without immunosuppression. The migration of USSCs was
determined by bioluminescent imaging (BLI) of RDEBmice as
well as excised internal organs.
Results: Asingle intra-hepatic injection ofUSSCs (0.2 x106) in
newborn RDEB mice arrested the blistering phenotype and
signiﬁcantly enhanced the median survival to 8 days (n¼21),
as compared to 2 days in PBS injected animals (n¼18)
(P<0.0001) (Figure 1). About 30% of the USSC-treated mice
lived beyond2weeks of life span and onemouse lived for four
weeks. Histological analysis on the footpad skin of the RDEB
mice demonstrated that the percentage of the skinwith intact
epidermis-dermis attachment was signiﬁcantly improved
from20% 6% onD0 to 70% 12% on day 5, afterwards after a
single intra-hepatic USSC injection. A second USSC intra-
hepatic injection further elongated the median life span (16
days, n¼ 18, P<0.0001) (Figure 1). Remarkably, twomice that
received repeated injections survivedmore than12weeks. BLI
of the RDEB mice following USSC injection further
demonstrated that USSCs rapidly went into circulation afterintra-hepatic injection and did not result in detectable
retention in heart, kidney, and spleen. Immunocytochemical
analysis revealed speciﬁc engraftment of USSCs in
gastrointestinal tract and the dermis and hair follicles of the
skin, suggesting a speciﬁc migration of USSCs toward the
sites of blisters. USSC injection also enhanced the expression
of C7 in the recipient skin and electron microscopy revealed
a partial restoration of anchoring ﬁbrils in skin biopsies
from the USSC-treated RDEB mice. We also demonstrated
that USSCs treatment induced an inﬁltration of
macrophages with a regenerative “M2” phenotype.
Conclusion: Our data suggest that HUCB-derived USSCs
improved the RDEB mucocutaneous manifestations in
col7a1-/- mice through multiple mechanisms. This study
warrants future clinical investigation of USSCs as a novel and
universal allogeneic stem cell donor source in selected
patients with RDEB.329
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Ex vivo expansion of human peripheral blood (PB) gamma
delta T cells, speciﬁcally the Vg9Vd2 subset, using aminobi-
sphosphonates (NBPs) has been extensively studied. Reports
suggest that NPBs can also stimulate human umbilical cord
blood (CB) gamma delta T cell proliferation ex vivo. However,
as CB gamma delta T cells are not well described in the
literature, we conducted a detailed comparison of CB gamma
